Form 4/A for XFOR X4 Pharmaceuticals, Inc
Accepted 2025-06-03 00:00:00 ET · period of report 2025-05-16 · accession 0001628280-25-029113 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2025-06-03 | 2025-05-16 | XFOR | Baldry Mark | Chief Commercial Off | A - Grant | $2.48 | +1,032 | 25.3K | +4% | +$2,559 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-16 | A | A | 1,032 | $2.48 | 25,337 | D | — | — | (F1) On May 16, 2025, the Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan at a price of $2.482 per share. Such transaction was exempt under both Rule 16b-3(d) and Rule 16b-3(c) of the Securities Exchange Act of 1934, as amended. |